Press Releases

Recipharm strengthens pre-filled syringe and cartridge offering with new investment

Oct 20, 2022, 10:14 AM by

END Contact information For media enquiries, please contact Imogen Quail, PR Manager, at ramarketing: imogen.quail@ramarketingpr.com, +44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing About Recipharm Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm and our services, please visit www.recipharm.com 1Source Safety Prefilled Syringe Market Size is expected to reach (globenewswire.com) Recipharm AB Corporate identity number 556498-8425 Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00 www.recipharm.com

Global contract development and manufacturing organisation (CDMO) Recipharm, has invested in a new high speed filling line for pre-filled syringes and cartridges at its facility in Wasserburg, Germany responding to increased customer demand in these high growth fill formats.

As part of a programme of recent investments and expansions across the wider business, this investment will further enhance Recipharm’s comprehensive manufacturing offering for injectable products that require sterile filling.

The leading sterile manufacturing facility specialises in more complex formats ranging from lyophilisation technology and aseptic filling into vials, syringes and cartridges.

The investment will expand Recipharm’s manufacturing footprint by adding a state-of-the-art, high-speed filling line for pre-filled syringes and cartridges. The line will be fully Annex 1 compliant and can support small volume projects as well as large.

Marc Funk, Chief Executive Officer at Recipharm said: “The investment at our Wasserburg facility demonstrates Recipharm’s commitment to meet ongoing customer demand for sterile filling capabilities. The demand for pre-filled syringes is rapidly growing, with the projected market value by 2030 expecting to reach USD 6.5 billion¹. We are proud to be able to offer such a comprehensive service to our customers spanning device design, development and manufacturing to drug product fill & finish, and look forward to continuing to simplify the journey to market for our customers and of course helping patients access vital medicines.”

The new line at Wasserburg is expected to be ready for technical trials by April 2023 with the first GMP batch run in May 2023 and is part of a wider growth plan which also sees the CDMO investing in new fill & finish facilities in France, Italy, India and Morocco.